<DOC>
	<DOCNO>NCT00811863</DOCNO>
	<brief_summary>The objective study prospectively monitor incidence adverse drug reaction , specifically NSF routine use gadoversetamide large number patient moderate renal insufficiency ( eGFR 30-59 ) severe renal insufficiency end-stage renal disease require dialysis ( eGFR &lt; 30 ) .</brief_summary>
	<brief_title>Evaluation Nephrogenic Systemic Fibrosis ( NSF ) Patients With Chronic Kidney Disease Following OptiMARK Injection</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Nephrogenic Fibrosing Dermopathy</mesh_term>
	<criteria>Referred contrastenhanced MRI use gadoversetamide ; Have document estimate glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73 m2 within past 6 month ESRD require dialysis ; Willing able provide write consent ( legally authorize representative ) agree abide study requirement , include see dermatologist undergo skin biopsy NSF suspect . Have experience previous hypersensitivity reaction GBCA ; Have preexist NSF NSFlike symptom ; Have expose GBCA within 12 month prior index procedure ; Has medical condition personal situation would prevent provide followup information , complete clinic visit otherwise supply meaningful data meet study objective .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Nephrogenic Systemic Fibrosis</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Gadoversetamide</keyword>
	<keyword>OptiMARK</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
</DOC>